<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEPO-TESTOSTERONE- testosterone cypionate injection, solution </strong><br>Pharmacia and Upjohn Company<br></p></div>
<h1>Depo<span class="Sup">®</span>-Testosterone<br> testosterone cypionate injection, USP  CIII</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone.</p>
<p>Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils.</p>
<p>The chemical name for testosterone cypionate is androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17β)-. Its molecular formula is C<span class="Sub">27</span>H<span class="Sub">40</span>O<span class="Sub">3</span>, and the molecular weight 412.61.</p>
<p>The structural formula is represented below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe808a56-7542-4d23-97b4-d98a3ef63016&amp;name=depo-01.jpg"></div>
<p>DEPO-Testosterone Injection is available as 200 mg/mL testosterone cypionate.</p>
<table class="Noautorules" width="70%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr><td align="left" colspan="2">Each mL of the<span class="Bold"> 200 mg/mL </span>solution contains:</td></tr>
<tr>
<td align="left">  Testosterone cypionate</td>
<td align="left">200 mg</td>
</tr>
<tr>
<td align="left">  Benzyl benzoate</td>
<td align="left">0.2 mL</td>
</tr>
<tr>
<td align="left">  Cottonseed oil</td>
<td align="left">560 mg</td>
</tr>
<tr>
<td align="left">  Benzyl alcohol (as preservative)</td>
<td align="left">9.45 mg</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Endogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of the prostate, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, and phosphorous, and decreased urinary excretion of calcium. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are responsible for the growth spurt of adolescence and for eventual termination of linear growth, brought about by fusion of the epiphyseal growth centers. In children, exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> accelerate linear growth rates, but may cause disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to stimulate production of red blood cells by enhancing production of erythropoietic stimulation factor.</p>
<p>During exogenous administration of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).</p>
<p>There is a lack of substantial evidence that <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are effective in <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, surgery, convalescence, and functional <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus, testosterone cypionate can be given at intervals of two to four weeks.</p>
<p>Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding globulin, and about 2 percent is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life.</p>
<p>About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6 percent of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone is metabolized to various 17-keto steroids through two different pathways.</p>
<p>The half-life of testosterone cypionate when injected intramuscularly is approximately eight days.</p>
<p>In many tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">DEPO-Testosterone Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone.</p>
<p>1. Primary <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired)-testicular failure due to <span class="product-label-link" type="condition" conceptid="437655" conceptname="Undescended testicle">cryptorchidism</span>, bilateral torsion, <span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span>, vanishing testis syndrome; or orchidectomy.</p>
<p>2. Hypogonadotropic <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired)- gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or radiation.</p>
<p>Safety and efficacy of DEPO-Testosterone (testosterone cypionate) in men with "age-related <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>" (also referred to as "late-onset <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>") have not been established.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol class="Arabic">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug</li>
<li>Males with carcinoma of the breast</li>
<li>Males with known or suspected carcinoma of the prostate gland</li>
<li>Women who are or who may become pregnant</li>
<li>Patients with serious cardiac, hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span></li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may occur in immobilized patients. If this occurs, the drug should be discontinued.</p>
<p>Prolonged use of high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> (principally the 17-α alkyl-<span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>) has been associated with development of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span>, hepatocellular carcinoma, and <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> —all potentially life-threatening complications.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk of developing <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma although conclusive evidence to support this concept is lacking.</p>
<p>There have been postmarketing reports of venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, including <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), in patients using testosterone products, such as testosterone cypionate. Evaluate patients who report symptoms of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, warmth and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> in the lower extremity for DVT and those who present with acute <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> for PE. If a venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> is suspected, discontinue treatment with testosterone cypionate and initiate appropriate workup and management.</p>
<p>Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, with the use of testosterone compared to non-use. Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men. Patients should be informed of this possible risk when deciding whether to use or to continue to use DEPO-Testosterone (testosterone cypionate).</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, with or without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, may be a serious complication in patients with pre-existing cardiac, renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> may develop and occasionally persists in patients being treated for <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>.</p>
<p>The preservative benzyl alcohol has been associated with serious adverse events, including the "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome", and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients. Although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the hepatic capacity to detoxify the chemical. Premature and low-birth weight infants may be more likely to develop toxicity. </p>
<p>Androgen therapy should be used cautiously in healthy males with <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every 6 months. In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height.</p>
<p>This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hypertrophy</span> may develop acute <span class="product-label-link" type="condition" conceptid="4318847" conceptname="Obstruction of urethra">urethral obstruction</span>. <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> or excessive sexual stimulation may develop. <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized.</p>
<p>Testosterone cypionate should not be used interchangeably with testosterone propionate because of differences in duration of action.</p>
<p>Testosterone cypionate<span class="Italics"> is not </span>for intravenous use.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.2"></a><p></p>
<h2>Information for patients</h2>
<p class="First">Patients should be instructed to report any of the following: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, changes in skin color, <span class="product-label-link" type="condition" conceptid="4144411" conceptname="Swollen ankle">ankle swelling</span>, too frequent or persistent erections of the penis.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.3"></a><p></p>
<h2>Laboratory tests</h2>
<p class="First">Hemoglobin and hematocrit levels (to detect <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>) should be checked periodically in patients receiving long-term androgen administration.</p>
<p>Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> may increase during androgen therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.4"></a><p></p>
<h2>Drug interactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>.</p>
<p>Concurrent administration of oxyphenbutazone and <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may result in elevated serum levels of oxyphenbutazone.</p>
<p>In diabetic patients, the metabolic effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may decrease blood glucose and, therefore, insulin requirements.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-6.5"></a><p></p>
<h2>Drug/Laboratory test Interferences</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may decrease levels of thyroxine-binding globulin, resulting in decreased total T<span class="Sub">4</span> serum levels and increased resin uptake of T<span class="Sub">3</span> and T<span class="Sub">4</span>. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.6"></a><p></p>
<h2>Carcinogenesis</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6.1"></a><p></p>
<h3>Animal data</h3>
<p class="First">Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of female mice increases their susceptibility to <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span>. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6.2"></a><p></p>
<h3>Human data</h3>
<p class="First">There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk of developing <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma although conclusive evidence to support this concept is lacking.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7.1.1"></a><p></p>
<h4>Pregnancy Category X</h4>
<p class="First">(See<a href="#contraindications"> CONTRAINDICATIONS</a>.)</p>
<p>Benzyl alcohol can cross the placenta. See<a href="#warnings"> WARNINGS</a>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.8"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">DEPO-Testosterone is not recommended for use in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.9"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 12 years have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions in the male have occurred with some <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>:</p>
<p>Endocrine and urogenital: <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> and excessive frequency and duration of penile erections. <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> may occur at high dosages.</p>
<p>Skin and appendages: <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span>, male pattern of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">baldness</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span>: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>: Retention of sodium, chloride, water, potassium, calcium, and <span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">inorganic phosphates</span>.</p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, alterations in liver function tests, rarely hepatocellular neoplasms and <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> (see<a href="#warnings"> WARNINGS</a>).</p>
<p>Hematologic: Suppression of clotting factors II, V, VII, and X, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients on concomitant anticoagulant therapy, and <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>.</p>
<p>Nervous system: Increased or decreased libido, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and generalized <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
<p>Allergic: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, including skin manifestations and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span>.</p>
<p>Miscellaneous: <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the site of intramuscular injection.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-8.1"></a><p></p>
<h2>Controlled Substance Class</h2>
<p class="First">Testosterone is a controlled substance under the Anabolic Steroids Control Act, and DEPO-Testosterone Injection has been assigned to Schedule III.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been no reports of acute overdosage with the <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Prior to initiating DEPO-Testosterone (testosterone cypionate), confirm the diagnosis of <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.</p>
<p>DEPO-Testosterone Injection is for intramuscular use only.</p>
<p>It should not be given intravenously. Intramuscular injections should be given deep in the gluteal muscle. </p>
<p>The suggested dosage for DEPO-Testosterone Injection varies depending on the age, sex, and diagnosis of the individual patient. Dosage is adjusted according to the patient's response and the appearance of adverse reactions.</p>
<p>Various dosage regimens have been used to induce pubertal changes in hypogonadal males; some experts have advocated lower dosages initially, gradually increasing the dose as puberty progresses, with or without a decrease to maintenance levels. Other experts emphasize that higher dosages are needed to induce pubertal changes and lower dosages can be used for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose.</p>
<p>For replacement in the hypogonadal male, 50–400 mg should be administered every two to four weeks.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warming and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> the vial should redissolve any crystals that may have formed during storage at temperatures lower than recommended.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">DEPO-Testosterone Injection is available as follows:</p>
<table class="Noautorules" width="75%">
<col align="right" valign="top" width="25%">
<col align="right" valign="top" width="25%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr>
<td align="left">200 mg/mL</td>
<td align="right"></td>
<td align="left"></td>
</tr>
<tr>
<td align="right">1 mL vials</td>
<td align="right"></td>
<td align="left">NDC 0009-0520-01</td>
</tr>
<tr>
<td align="right">10 mL vials</td>
<td align="right"></td>
<td align="left">NDC 0009-0520-10</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Vials should be stored at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]. Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Distributed by<br>Pharmacia &amp; Upjohn Co<br>Division of Pfizer Inc<br>New York, NY 10017</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe808a56-7542-4d23-97b4-d98a3ef63016&amp;name=depo-02.jpg"></p>
<p>PREMIERProRx™ is a trademark of Premier, Inc., used under license.</p>
<p>LAB-0711-6.0<br>April 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mL Vial Label</h1>
<p class="First"><span class="Bold">10 mL Vial<br>Multiple-Dose</span></p>
<p>NDC 0009-0520-10</p>
<p><span class="Bold">Depo</span><span class="Sup">®</span><span class="Bold">-<br>Testosterone</span><br>testosterone cypionate<br>injection, USP</p>
<p><span class="Bold">CIII</span></p>
<p><span class="Bold">200 mg/mL</span></p>
<p>For intramuscular use only</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">PREMIER</span>ProRx™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe808a56-7542-4d23-97b4-d98a3ef63016&amp;name=depo-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton</h1>
<p class="First">NDC 0009-0520-10</p>
<p><span class="Bold">One 10 mL Vial<br>Multiple-Dose</span></p>
<p><span class="Bold">Depo</span><span class="Sup">®</span><span class="Bold">-<br>Testosterone</span><br>						testosterone cypionate<br>injection, USP</p>
<p><span class="Bold">CIII</span></p>
<p><span class="Bold">200 mg/mL</span></p>
<p>For intramuscular<br>use only</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">PREMIER</span>ProRx™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe808a56-7542-4d23-97b4-d98a3ef63016&amp;name=depo-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEPO-TESTOSTERONE 		
					</strong><br><span class="contentTableReg">testosterone cypionate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0009-0520</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TESTOSTERONE CYPIONATE</strong> (TESTOSTERONE) </td>
<td class="formItem">TESTOSTERONE CYPIONATE</td>
<td class="formItem">200 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL BENZOATE</strong></td>
<td class="formItem">0.2 mL  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COTTONSEED OIL</strong></td>
<td class="formItem">560 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">9.45 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0009-0520-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0009-0520-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA085635</td>
<td class="formItem">03/31/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pharmacia and Upjohn Company
							(829076566)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">ANALYSIS(0009-0520), API MANUFACTURE(0009-0520), LABEL(0009-0520), MANUFACTURE(0009-0520), PACK(0009-0520)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2ff62701-0be4-4a3f-9530-fa8acb4d1c7b</div>
<div>Set id: fe808a56-7542-4d23-97b4-d98a3ef63016</div>
<div>Version: 6</div>
<div>Effective Time: 20150806</div>
</div>
</div> <div class="DistributorName">Pharmacia and Upjohn Company</div></p>
</body></html>
